What is the clinical evidence from this study?

Study design: Other. Population: Renal cell carcinoma (n=136). Intervention: Sorafenib vs. No therapy. Primary outcome: Progression-free survival in patients with high ANGPTL3 expression (p=0.0084).

July 19, 2018British Journal of CancerOpen Access

Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response

View Full Paper

Ask AI

Bookmark

Key result

High ANGPTL3 expression in renal cell carcinoma tissues predicted a significant improvement in progression-free survival for patients receiving sorafenib therapy.

Population

224 RCC patients and preclinical models.

Comparison

Sorafenib treatment combined with ANGPTL3… vs Control groups

Design

Preclinical

Authors

YBYi BaoGuangxi Medical University FYFu YangMinistry of Defence BLBing LiuThird Affiliated Hospital of Guangzhou Medical University

Discussion

Member takes

Implication

May support ANGPTL3 targeting to restore sorafenib sensitivity in RCC; hypothesis-generating, requires clinical validation.

Structured PICO

Population

136 patients with advanced clear cell renal cell carcinoma, evaluated for the predictive value of ANGPTL3 expression on progression-free survival following sorafenib therapy.

Exposure

Sorafenib treatment combined with ANGPTL3 modulation (knockdown or overexpression)

Comparator

Control groups (vehicle, non-targeting shRNA, or empty vector)

Outcome

Sorafenib sensitivity (measured by IC50, cellular apoptosis, and tumor volume in xenografts)surrogate

Main Result

p-value: p=0.0084

ANGPTL3 is a potential predictive biomarker and therapeutic target for overcoming sorafenib resistance in renal cell carcinoma.

Limitations

Differences in experimental environments between in vitro and in vivo settings may have affected proteome microarray outcomes.

Cite This Study

Bao et al. (2018) studied Renal cell carcinoma (n=136). Sorafenib vs. No therapy was evaluated on Progression-free survival in patients with high ANGPTL3 expression (p=0.0084). High ANGPTL3 expression in renal cell carcinoma tissues predicted a significant improvement in progression-free survival for patients receiving sorafenib therapy.

synapsesocial.com/papers/6a930e5184ae171528c6b006 https://doi.org/10.1038/s41416-018-0189-4

View Full Paper

Ask AI

Bookmark

Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider